b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">31012962</PMID>\n        <DateCompleted>\n            <Year>2020</Year>\n            <Month>05</Month>\n            <Day>18</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>05</Month>\n            <Day>18</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1097-0142</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>125</Volume>\n                    <Issue>16</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>08</Month>\n                        <Day>15</Day>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Cancer</Title>\n                <ISOAbbreviation>Cancer</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>A phase 1 trial of the oral DNA methyltransferase inhibitor CC-486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>2837-2845</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1002/cncr.32138</ELocationID>\n            <Abstract>\n                <AbstractText Label="BACKGROUND">Epigenetic abnormalities are manifold in all solid tumors and include changes in chromatin configuration and DNA methylation. The authors designed a phase 1 study to evaluate the oral DNA methyltransferase inhibitor CC-486 combined with the histone deacetylase inhibitor romidepsin in advanced solid tumors with dose expansion to further evaluate pharmacodynamics and possible clinical benefit of the recommended phase 2 dose (RP2D).</AbstractText>\n                <AbstractText Label="METHODS">This was a phase 1 study with a 3\xc2\xa0+\xc2\xa03 dose-escalation design and an expansion phase for patients with virally mediated cancers. The disease control rate (DCR) was the primary outcome for the expansion cohort. Correlative studies included long interspersed nucleotide element 1 (LINE-1) methylation and drug exposure in blood samples (clinicaltrials.gov identifier NCT01537744).</AbstractText>\n                <AbstractText Label="RESULTS">Fourteen patients were enrolled in the dose-escalation portion at 3 dose levels. Three patients experienced dose-limiting toxicities; the RP2D was oral CC-486 300\xc2\xa0mg daily on days 1 through 14 and romidepsin 8\xc2\xa0mg/m<sup>2</sup> on days 8 and 15. Because of slow accrual into the expansion phase, the trial was closed after 4 patients enrolled. Common toxicities of the combination included nausea (83.3%), anorexia (72.2%), fatigue (61.1%), and constipation (55.6%). There were 12 patients evaluable for response, 5 with stable disease, of whom 2 received &gt;4 cycles; there were no responses. Exposure to CC-486 and romidepsin was consistent with prior data. LINE-1 methylation on C1D8 was significantly reduced (mean, -6.23; 95% CI, -12.23, -0.24; P\xc2\xa0=\xc2\xa0.04).</AbstractText>\n                <AbstractText Label="CONCLUSIONS">Although, at the RP2D, the combination of CC-486 and romidepsin was tolerable, no significant anticancer activity was observed. Significant demethylation in post-treatment circulating tumor DNA and biopsies provided proof of target acquisition.</AbstractText>\n                <CopyrightInformation>\xc2\xa9 2019 American Cancer Society.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Gaillard</LastName>\n                    <ForeName>St\xc3\xa9phanie L</ForeName>\n                    <Initials>SL</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Zahurak</LastName>\n                    <ForeName>Marianna</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Oncology, Division of Biostatistics and Bioinformatics, Johns Hopkins School of Medicine, Baltimore, Maryland.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Sharma</LastName>\n                    <ForeName>Anup</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Surgery, Division of Surgical Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Durham</LastName>\n                    <ForeName>Jennifer N</ForeName>\n                    <Initials>JN</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Reiss</LastName>\n                    <ForeName>Kim A</ForeName>\n                    <Initials>KA</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Sartorius-Mergenthaler</LastName>\n                    <ForeName>Susan</ForeName>\n                    <Initials>S</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Downs</LastName>\n                    <ForeName>Melinda</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Anders</LastName>\n                    <ForeName>Nicole M</ForeName>\n                    <Initials>NM</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Ahuja</LastName>\n                    <ForeName>Nita</ForeName>\n                    <Initials>N</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Surgery, Division of Surgical Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Rudek</LastName>\n                    <ForeName>Michelle A</ForeName>\n                    <Initials>MA</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Medicine, Division of Clinical Pharmacology, Johns Hopkins School of Medicine, Baltimore, Maryland.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Azad</LastName>\n                    <ForeName>Nilofer</ForeName>\n                    <Initials>N</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Department of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <DataBankList CompleteYN="Y">\n                <DataBank>\n                    <DataBankName>ClinicalTrials.gov</DataBankName>\n                    <AccessionNumberList>\n                        <AccessionNumber>NCT01537744</AccessionNumber>\n                    </AccessionNumberList>\n                </DataBank>\n            </DataBankList>\n            <GrantList CompleteYN="Y">\n                <Grant>\n                    <GrantID>UL1 TR001863</GrantID>\n                    <Acronym>TR</Acronym>\n                    <Agency>NCATS NIH HHS</Agency>\n                    <Country>United States</Country>\n                </Grant>\n                <Grant>\n                    <GrantID>S10 RR026824</GrantID>\n                    <Acronym>RR</Acronym>\n                    <Agency>NCRR NIH HHS</Agency>\n                    <Country>United States</Country>\n                </Grant>\n                <Grant>\n                    <GrantID>UL1 TR001079</GrantID>\n                    <Acronym>TR</Acronym>\n                    <Agency>NCATS NIH HHS</Agency>\n                    <Country>United States</Country>\n                </Grant>\n                <Grant>\n                    <GrantID>P30 CA006973</GrantID>\n                    <Acronym>CA</Acronym>\n                    <Agency>NCI NIH HHS</Agency>\n                    <Country>United States</Country>\n                </Grant>\n            </GrantList>\n            <PublicationTypeList>\n                <PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>\n                <PublicationType UI="D013485">Research Support, Non-U.S. Gov\'t</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>04</Month>\n                <Day>23</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>Cancer</MedlineTA>\n            <NlmUniqueID>0374236</NlmUniqueID>\n            <ISSNLinking>0008-543X</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D047630">Depsipeptides</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D056572">Histone Deacetylase Inhibitors</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>CX3T89XQBK</RegistryNumber>\n                <NameOfSubstance UI="C087123">romidepsin</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>EC 2.1.1.-</RegistryNumber>\n                <NameOfSubstance UI="D008780">Methyltransferases</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>AIM</CitationSubset>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000855" MajorTopicYN="N">Anorexia</DescriptorName>\n                <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>\n                <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>\n                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>\n                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D047630" MajorTopicYN="N">Depsipeptides</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>\n                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>\n                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D056572" MajorTopicYN="N">Histone Deacetylase Inhibitors</DescriptorName>\n                <QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName>\n                <QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName>\n                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D020084" MajorTopicYN="N">Long Interspersed Nucleotide Elements</DescriptorName>\n                <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D020714" MajorTopicYN="N">Maximum Tolerated Dose</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008780" MajorTopicYN="N">Methyltransferases</DescriptorName>\n                <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D009325" MajorTopicYN="N">Nausea</DescriptorName>\n                <QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="Y">CC-486</Keyword>\n            <Keyword MajorTopicYN="Y">DNA methyltransferase (DNMT) inhibitors</Keyword>\n            <Keyword MajorTopicYN="Y">epigenetic therapy</Keyword>\n            <Keyword MajorTopicYN="Y">histone deacetylase (HDAC) inhibitors</Keyword>\n            <Keyword MajorTopicYN="Y">phase 1 clinical trial</Keyword>\n            <Keyword MajorTopicYN="Y">romidepsin</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2019</Year>\n                <Month>01</Month>\n                <Day>30</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="revised">\n                <Year>2019</Year>\n                <Month>03</Month>\n                <Day>07</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2019</Year>\n                <Month>03</Month>\n                <Day>08</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pmc-release">\n                <Year>2020</Year>\n                <Month>08</Month>\n                <Day>15</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>4</Month>\n                <Day>24</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2020</Year>\n                <Month>5</Month>\n                <Day>19</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>4</Month>\n                <Day>24</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">31012962</ArticleId>\n            <ArticleId IdType="doi">10.1002/cncr.32138</ArticleId>\n            <ArticleId IdType="pmc">PMC6663621</ArticleId>\n            <ArticleId IdType="mid">NIHMS1020600</ArticleId>\n        </ArticleIdList>\n        <ReferenceList>\n            <Reference>\n                <Citation>Curr Opin Genet Dev. 1999 Apr;9(2):171-4</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">10322142</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Mol Pharmacol. 2001 Apr;59(4):751-7</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">11259619</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Nat Genet. 2002 Jun;31(2):141-9</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">11992124</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Int J Cancer. 2003 Jan 10;103(2):177-84</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">12455031</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cancer Res. 2003 Nov 1;63(21):7089-93</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">14612500</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>N Engl J Med. 2003 Nov 20;349(21):2042-54</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">14627790</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Nucleic Acids Res. 2004 Feb 18;32(3):e38</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">14973332</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Oncol. 2005 Jun 10;23(17):3906-11</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">15851763</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cell Res. 2005 Apr;15(4):262-71</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">15857581</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cancer Res. 2006 Jun 15;66(12):6361-9</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">16778214</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Mol Cell Biol. 2008 Jan;28(2):752-71</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">17991895</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Clin Cancer Res. 2008 Oct 1;14(19):6296-301</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">18829512</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Clin Cancer Res. 2009 Oct 1;15(19):6241-9</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">19789320</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Clin Chem. 2010 Jun;56(6):1022-5</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">20360128</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Oncol. 2011 Jun 20;29(18):2521-7</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">21576646</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cancer Discov. 2011 Dec;1(7):598-607</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">22586682</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Oncol. 2013 Jun 10;31(17):2128-35</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">23650416</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Pharmacol. 2015 Dec;55(12):1378-85</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26053962</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Biomed Chromatogr. 2016 Mar;30(3):494-6</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26174363</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cell. 2015 Aug 27;162(5):961-73</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26317465</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cell. 2015 Aug 27;162(5):974-86</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">26317466</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Clin Cancer Res. 2017 Jun 1;23(11):2691-2701</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">27979916</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Oncotarget. 2017 May 23;8(21):35326-35338</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">28186961</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Proc Natl Acad Sci U S A. 2017 Dec 19;114(51):E10981-E10990</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29203668</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cell Cycle. 2018;17(7):811-822</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29633898</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Clin Cancer Res. 2018 Sep 1;24(17):4072-4080</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">29764853</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cell. 1995 Apr 21;81(2):197-205</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">7537636</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Nat Genet. 1999 Jan;21(1):103-7</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">9916800</ArticleId>\n                </ArticleIdList>\n            </Reference>\n        </ReferenceList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'